San Francisco, 18 December 2024: The Report U.S. Biopharmaceutical Third-party Logistics Market Size, Share & Trends Analysis Report By Supply Chain (Cold Chain, Non-cold Chain), By Service (Transportation, Warehousing & Storage), By Product (Specialty Drugs, Plasma Derived Products), And Segment Forecasts, 2030 - 2030

The U.S. biopharmaceutical third-party logistics market size is estimated to reach USD 87.44 billion by 2030, registering to grow at a CAGR of 7.56% from 2030 to 2030 according to a new report by Grand View Research, Inc. Increasing demand for novel biologics and the need to manage those is boosting the market growth. Besides, rising demand for temperature-controlled logistic services to transport biologics in various regions and growing distribution networks of biopharmaceutical companies to improve their sales are factors driving the growth.

The COVID-19 pandemic has had a major impact on global logistics to some extent due to diminished air freight capacity and reduced workforce at warehouses and airports. The decisions of local authorities to shut down the logistic infrastructure, enforce movement restrictions, or put in place additional requirements to suppress transmission of the virus have also impacted the logistic services. This has significantly hindered many supply operations.

The future seems lucrative for the biopharmaceutical third-party logistics industry in the U.S. with the retraction of government regulations related to transportation and shelter-in-place mandates. A sudden surge in the demand for cold chain logistics was observed during the pandemic. Growth in the manufacture and distribution of the COVID-19 vaccine is expected throughout 2021. For instance, in March 2021, FedEx Express started shipping COVID-19 vaccines for McKesson Corp. to centers all across the U.S. The company has already shipped millions of COVID-19 vaccines since mid-December 2020.

The market is experiencing lucrative growth due to the increasing trend of outsourcing logistics, pharmaceutical companies' importance for strong distribution networks owing to strong sales numbers, and a surge in the number of biosimilar launches. Further, the growing demand for biologics and specialty drugs, which require stringent temperature control, has significantly boosted the need for advanced cold-chain logistics solutions. Increasing regulatory requirements for storing and transporting biopharmaceutical products, particularly with the rise of precision medicine, are likely to contribute to market growth. The COVID-19 pandemic highlighted the importance of efficient supply chain solutions, further accelerating investments in 3PL services to ensure the timely delivery of vaccines and critical medicines.

Request sample report of U.S. Biopharmaceutical Third-party Logistics Market@ https://www.grandviewresearch.com/industry-analysis/us-biopharmaceutical-third-party-logistics-market-report/request/rs1

Moreover, biopharmaceutical companies are increasingly outsourcing logistics functions to 3PL providers to focus on core activities such as drug development to limit operational costs and enhance efficiency, thereby accelerating market demand. The rapid advancement of technology, including real-time monitoring systems and IoT-enabled devices used to enhance the visibility and safety of pharmaceutical products in transit and improve supply chain management, positively influence the market growth potential in the near future. These advanced technologies reduce human errors and safeguard product integrity by ensuring precise temperature management throughout the supply chain. By integrating advanced systems, 3PL providers automate operations and ensure compliance with strict pharmaceutical regulations, further driving market demand. Additionally, the rise in personalized medicine and direct-to-patient distribution models is prompting a shift towards more specialized and flexible logistics services, propelling the growth of the U.S. biopharmaceutical third-party logistics market.

U.S. Biopharmaceutical Third-party Logistics Market Highlights

• The non-cold chain logistics segment accounted for the largest revenue share of 58.39% in 2024. The segment is primarily driven by the distribution of standard biopharmaceutical products that do not require stringent temperature control, allowing for a broader range of transportation and storage options.
• The warehousing and storage segment dominated the market in 2024. This segment provides specialized storage solutions for both temperature-sensitive and non-sensitive products, integrating high-tech systems such as automated warehouses and real-time inventory management.
• The specialty drugs segment accounted for the largest revenue share in the market in 2024 and is expected to witness the highest CAGR over the estimated timeline. This is attributed to the unique handling requirements of these high-value, often temperature-sensitive medications.

The COVID-19 pandemic acted as a major catalyst in driving the U.S. market, particularly in the cold chain sector. The development and distribution of COVID-19 vaccines, especially those requiring ultra-low temperatures, highlighted the need for innovative temperature-controlled packaging and logistics solutions. During the pandemic, the sudden surge in demand for cold chain logistics accelerated the adoption of advanced technologies and practices, expanding the market's capacity to handle biologics and other temperature-sensitive drugs. The market is expected to boost with enhanced capabilities in managing cold chain logistics with the growing adoption of vaccines and other biologics.

The growing need for reverse logistics in biopharmaceuticals owing to increased product recalls and shorter product life cycles creates ample market growth opportunities. Reverse logistics, especially in drug returns and recalls, is essential for efficiently managing unused or expired medications. Environmental concerns and cost optimization fuel demand for reverse logistics, ensuring safe disposal or redistribution of pharmaceutical products. As service management activities increase, 3PL providers enhance their reverse logistics services, making it a critical factor in market revenue growth.

U.S. Biopharmaceutical Third-party Logistics Market Report Scope

The demand for outsourcing transportation services has grown significantly over the last few years. Outsourcing transportation services for distributing pharmaceutical drugs has reduced the overheads of large biopharmaceutical companies. Furthermore, the big biopharma companies outsource to 3PL service providers to reduce the overall operating cost, promote lean management, and apply Six Sigma in their business operations. This, in turn, is expected to lower the prices of pharmaceutical products, positively propelling market demand.